Kugona kwemannose mumunda wemishonga kunonyanya kutariswa munzira dzakati wandei, dzimwe dzakatoiswa mukiriniki (zvakadai sekudzivirira hutachiona hweurinary tract), nepo vamwe vari mukutanga tsvagiridzo kana yekutanga kiriniki yekuyedza nhanho. Tarisiro yacho inofanirwa kutariswa, asi humbowo hwakawanda hunodiwa kuti utsigire. Rondedzera kugona kwayo munzvimbo dzinotevera:

?

1, Kuzivikanwa/Kukura Kwekushandisa Minda

Kudzivirira zvirwere zvinogara zvichiitika weti (rUTI) ?

Mechanism: Kudzora nemuromo kwemannose kunoguma nekukwira kwakanyanya muweti, nemakwikwi kuvharira kusungwa kweFimH pilin adhesins kubva kune hutachiona hwakadai seEscherichia coli kune dundira epithelial masero, kudzivirira mabhakitiriya kubva mukoloni uye kusukwa neweti.

Umbowo:

Zvidzidzo zvekiriniki zvakawanda, zvakadai sekuenzanisa nemishonga inorwisa mabhakitiriya furantoin, yakaratidza kuti 1.5-2g yemannose pazuva inoshanda seyakaderera-dose antibiotics mukudzivirira rUTI inokonzerwa neEscherichia coli muvakadzi, uye ine ngozi yakaderera yekudzivirira.

European Association of Urology (EAU) nhungamiro inonyora seimwe nzira yekudzivirira rUTI (Chiyero cheUchapupu: B).

Zvakanakira: Kuchengetedzeka kwepamusoro (zvinyoro mudumbu mhedzisiro), hapana njodzi yehupamhi-spectrum antibiotic kuramba.

Zvisingakwanisi: Inoshanda chete pakudzivirira uye haigoni kutsiva mishonga inorwisa mabhakitiriya mukurapa zvirwere zvakanyanya; Mhedzisiro pane isiri Escherichia coli UTI ishoma.

2、 Nzvimbo dziri mudanho rekutsvagisa asi zvine mukana wakajeka

Kurapa kweCongenital Glycation Disorder (CDG)

?

Mechanism: Mamwe maCDG subtypes, akadai seMPI-CDG (CDG-Ib type), kushaya phosphomannose isomerase (PMI), iyo inodzivirira kutendeuka kwemannose-6-phosphate kune fructose-6-phosphate, zvichiita kuti nhengo dzakawanda dzikundike.

Kurapa: Kutungamirirwa kwemuromo kwemannose kunogona kudarika PMI kukanganisa uye kupa zvakananga mannose-6-phosphate, kudzorera glycoprotein synthesis.

Mamiriro azvino

Iyo FDA yakabvumidza kushandiswa kwemannose yeMPI-CDG, inova imwe yemashoma mashoma anorapika eCDG.

Kuvandudzika kunokosha muchirwere chechiropa, kusashanda zvakanaka kwechiropa, uye zviratidzo zvomudumbu, asi mushonga woupenyu hwose unodiwa.

Zvinogona: Ongorora iyo adjuvant therapeutic value kune mamwe maCDG subtypes, senge ALG-CDG.

Antitumor immune regulation uye kuendesa zvinodhaka ???? (Active preclinical research)

?

Mechanism:

Targeted tumor microenvironment: Tumor inobatanidza macrophages (TAMs) inonyanya kuratidza mannose receptors (MRC1), uye mannose yakagadziridzwa mishonga inogona kuendeswa kumamota nenzira yakanangwa.

Kudzora kudzvinyirirwa kwekudzivirira: Mannose inokwikwidza inodzivirira mannose receptors pamusoro peTAMs, ichivharira kucherechedzwa kwavo kwemannose glycated antigens pamusoro pemamota masero, ayo anogona kudzoreredza kudzvanywa kwemuviri.

Enhancing chemotherapy sensitivity: Muzvidzidzo zvemhuka, kusanganiswa kwemannose uye chemotherapy (yakadai sedoxorubicin) inogona kuvharidzira zvakanyanya bundu kukura (zvichida nekukanganisa glucose metabolism).

Dambudziko: Kumwe kutsvagisa kunodiwa pakubudirira kwevanhu, yakakwana dosage, uye masisitimu ekutumira.

Antifungal/antiparasitic infection adjuvants ??

?

Mechanism: Zvirwere zvakadai seCandida albicans nePlasmodium zvinotsamira pane zvinogamuchira mannose receptors kuti zvipinde mumasero. Mannose inogona kuvhara kunamatira kwayo.

Tsvagiridzo:

In vitro uye mhuka mhando dzakaratidza kuti mannose inogona kuvharira Candida kunamatira kune epithelial masero.

Kushandiswa kwakabatanidzwa nemishonga inorwisa marariya kunogona kuderedza kuwanda kweutachiona hwemarariya (kuedza kwemhuka).

Zvinogoneka: Semubatsiri wekusimudzira kushanda kweiyo iripo anti infective mishonga uye kuderedza kuramba zvinodhaka.

3, Mafambiro ekuongorora ari kubuda (anogona kusimbiswa)

Chirwere chekuzvimba bowel (IBD) uye kugadzirwa kwemukati memukati ??

?

Kufungidzira:

Mannose inogona kudzora gut microbiota (inosimudzira mabhakitiriya anobatsira) uye inhibit pathogenic bhakitiriya kunamatira.

Kuvandudza basa remukati mucosal barriers mapuroteni kuburikidza nekugadzirisa glycosylation.

Mamiriro ezvinhu aripo: Mhuka dzemhando (colitis) dzinoratidza zvimwe zvinodzivirira, asi kutsvagisa kwevanhu kuri kushomeka.

Kudzorwa kwezvirwere zve autoimmune ??

?

Dzidziso: Abnormal glycosylation inobatanidzwa mune pathogenesis yerheumatoid arthritis, lupus, uye zvimwe zvirwere. Mannose supplementation inogona kugadzirisa glycosylation defects.

Kufambira mberi: Inongocherechedzwa mumasero modhi kana nhamba diki kwazvo yezviitiko, pasina kuomarara kuyedzwa kwekiriniki.

Kudzivirirwa kwematambudziko echirwere cheshuga ??

?

Logic: Shuga yepamusoro yeropa inotungamira kune yakawandisa isiri enzymatic glycation (AGEs) yemapuroteni, zvichikonzera matambudziko. Mannose metabolism haina kutsamira pane insulin uye haina kukanganisa shuga yeropa, kana inogona kukwikwidza kuderedza kuumbwa kweAGE.

Uchapupu: Kuedza kwemhuka kunoratidza kuti kufambira mberi kwechirwere cheshuga nephropathy kunononoka, uye tsvakurudzo yevanhu haina chinhu.

4, Zvinetso uye zvisingakwanisi

Matambudziko makuru mumunda

Kudzivirirwa kweUTI hakushandi kurwisa utachiona husina Escherichia coli; Yenguva refu yekuchengetedza data haina kukwana (kunyanya renal function impact)

Kurapa kweCDG kunoshanda chete kune chaiwo subtypes; Kukurumidza kuongororwa uye mishonga yeupenyu hwose inodiwa

Kubudirira kwekurapwa kwebundu mumuviri wemunhu hazvizivikanwe; Kuwedzerwa kwemishonga kunogona kukonzera manyoka; Ngozi yehupfu yekubatanidza chemotherapy inoda kuongororwa

Kusakwana kwekuita kwekushandiswa kumwe chete kwe anti infective adjuvants; Inoda kukwidziridza mushonga wekusanganisa nemishonga iripo

Tsvagiridzo isina simba pamusoro pemichina mune dzimwe nzvimbo dziri kubuda; Kushaikwa kwemhando yepamusoro yekiriniki miedzo; Vazhinji vavo vanoramba vari muchikamu chemuenzaniso wemhuka

5 、 Remangwana rekusimudzira gwara

Precision yekuendesa sisitimu yekuvandudza: Dhizaini mannose yakagadziridzwa nanocarriers kuti iwedzere bundu / inotapukira lesion yakanangana.

Combination therapy optimization: kuongorora synergistic mhedzisiro yemannose nemishonga inorwisa mabhakitiriya, immune checkpoint inhibitors, uye antifungal zvinodhaka.

Rare Disease Kuwedzera: Kuongororwa kwemamwe maCDG subtypes uye lysosomal kuchengetedza kusagadzikana kunogona kurapwa nemannose.

Kureba kuita kwakasimba-kusunungurwa kuumbwa: kunogadzirisa dambudziko rekugara uchirapa (sekushandiswa kwezuva nezuva kweUTI kudzivirira).

Population stratification strategy: chaiyo mishonga yakavakirwa pathogen type (UTI) kana gene mutation (CDG)